Skip to main content

BridgeBio Oncology Therapeutics, Inc.

BBOT
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001869105

In the last 90 days, BridgeBio Oncology Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 88 institutions reported holding it in 13F filings for Q3 2026, worth $246.7M in total; no superinvestor holds it.

Key figures

Market capClose on Nov 19, 2026
$149.3M
Insider buysOpen market, last 90 days
0
Insider sellsLast 90 days, $184.86 in total
1
13F holdersQ3 2026, +24 vs. previous quarter
88
13F valueReported value at the end of Q3 2026
$246.7M
Superinvestors holdingAt the end of Q3 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2025
$11.3M
No comparable prior period
Net income, FY2025
-$134.0M
−1,863.9% year over year
Free cash flow, FY2025
-$114.5M
No comparable prior period
Revenue, Q3 FY2026
$3.26M
−5.3% year over year

Revenue flow, FY2025

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2025: $134.0M (1181.7% of revenue).

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
3.47M
Shares sold short
Change
−377.8K
−9.8% vs. previous
Days to cover
5.10
At average daily volume

Superinvestors holding BBOT, Q3 2026

Go to the superinvestors tab

No superinvestor reported holding BBOT at the end of Q3 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by BridgeBio Oncology Therapeutics, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 17, 2026 (view filing)4:35 PM ETNov 134 daysCobo MarcPrincipal Accounting OfficerSSale−78$2.37−$184.86−0.6%13.7K after10b5-1
Feb 13, 2024 (view filing)Feb 13Same dayChen BihuaCEO and ChairpersonPPurchaseClass A Ordinary Shares+2.40M$10.00+$24.0MNew position903.6K after3 lots

Top 10 13F holders, Q3 2026

See all 88 holders

The largest institutional positions in BridgeBio Oncology Therapeutics, Inc. at the end of Q3 2026; share changes are against Q2 2026.

Institutions holding BBOT in Q3 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Cormorant Asset Management, LP17,878,594$73.3M4.92%00.0%Unchanged
BlackRock, Inc.4,009,791$16.4M0.00%+1,855,751+86.2%Added
Omega Fund Management, LLC3,289,661$13.5M10.78%00.0%Unchanged
Deerfield Management Company, L.P. (Series C)3,138,167$12.9M0.20%−1,747,279−35.8%Reduced
Alphabet Inc.2,823,126$11.6M0.01%00.0%Unchanged
Citadel Advisors LLC2,697,077$11.1M0.01%+79,250+3.0%Added
Enavate Sciences GP, LLC2,626,946$10.8M3.85%00.0%Unchanged
Regents of the University of California2,509,446$10.3M0.15%+2,509,446New
Armistice Capital, LLC2,264,000$9.28M0.31%+500,000+28.3%Added
Novo Holdings A/S2,250,000$9.22M0.62%00.0%Unchanged

Holders of 5% or more of BBOT

See all 7 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of BridgeBio Oncology Therapeutics, Inc..

Largest holders of BBOT from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Helix Holdings II LLC13D/A31.59%7.39M shares–Feb 20, 20242 filingsMar 4, 2025SEC
Helix Holdings II LLC13D/A22.60%17.9M shares–Aug 13, 20251 filingAug 13, 2025SEC
Chen Bihua13D/A22.32%17.9M shares–Jul 6, 20261 filingJul 6, 2026SEC
BridgeBio Pharma LLC13D17.50%13.9M sharesNewAug 18, 20251 filingAug 18, 2025SEC
BlackRock Portfolio Management LLC13G7.90%1.50M sharesNewApr 15, 20251 filingApr 15, 2025SEC